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Abstract
Purpose Chemotherapy-induced neutropenia is a serious and
potentially life-threatening consequence of cancer treatment.
Prophylactic treatment with granulocyte-colony stimulating
factor (G-CSF) decreases the incidence of febrile neutropenia,
the rate of hospitalization, and the use of antibiotics in patients
at risk. The aim of this study was to assess efficacy, safety, and
use of Zarzio®—biosimilar of Neupogen® (G-CSF;
filgrastim)—in prophylaxis of chemotherapy-induced neutro-
penia in current practice in cancer patients.
Methods We conducted an observational, prospective, longi-
tudinal, and multicentric study in France. The incidence of
neutropenia was evaluated at each cycle of chemotherapy.
Results One hundred eighty-four patients (women, 64.7 %;
mean age, 61.7 years) with solid tumor (89.7 %; breast
cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were
included. The risk of febrile neutropenia based on chemo-
therapy regimen was >20 % for 32.1 % of patients. No case
of febrile neutropenia was reported. Neutropenia was the
cause of hospitalization and/or antibiotic therapy in 10 pa-
tients. The most frequent adverse events related to Zarzio®
were pain, in particular bone pain. No serious adverse
event related to Zarzio® was reported.
Conclusion The results obtained in real-life conditions
confirm that Zarzio® is efficient and well tolerated in
cancer patients.
Keywords Chemotherapy-induced neutropenia . Filgrastim .
Biosimilar . Observational study . Zarzio®
Introduction
Chemotherapy-induced neutropenia is a serious and po-
tentially life-threatening consequence of cancer treatment
because sepsis or severe infections are possible complica-
tions; neutropenia is generally observed during the first
cycles of chemotherapy [1–6]. Moreover, delays and dose
reductions of chemotherapy due to neutropenia in subse-
quent treatment cycles compromise efficacy [7–11].
Prophylactic administration of antibiotics significantly
reduces the incidence of febrile neutropenia and mortality
related to infections [12]. Antibiotic prophylaxis to prevent
infection and infection-related complications in cancer pa-
tients at risk of febrile neutropenia is however controversial
due to possible emergence of antibiotic resistance. The guide-
lines of the European Organization for Research and Treat-
ment of Cancer (EORTC) do not recommend systematic
administration of prophylactic administration of antibiotics
[13]. An alternative approach is the prophylactic treatment
with granulocyte-colony stimulating factor (G-CSF;
filgrastim, lenograstim, pegfilgrastim) which decreases
the incidence of febrile neutropenia, the rate of hospitali-
zation, and the use of antibiotics in patients at risk [14].
The use of G-CSF in the prevention of chemotherapy-
induced febrile neutropenia has been defined in different
international guidelines. The guidelines of the American
Society of Oncology (ASCO) in 2006 and those of the
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National Comprehensive Cancer Network (NCCN) in
2014 recommend the use of G-CSF in primary prophylaxis
for chemotherapy associated with a risk of febrile neutro-
penia ≥20 % [15, 16]. The 2006 guidelines of EORTC
updated in 2010 recommend the systematic use of G-CSF
in primary prophylaxis to prevent febrile neutropenia if the
risk of febrile neutropenia associated with the cytotoxic
chemotherapy is ≥20 %, but also on a case-by-case basis
if the cytotoxic chemotherapy induces a risk from 10 to
20 % [13]. In this case, the recommendations take into ac-
count patient-related risk factors that may increase the overall
risk of febrile neutropenia such as age above 65 years.
Zarzio® is a biosimilar of filgrastim (Neupogen®). This
biosimilarity has been demonstrated in analytical tests that
assessed the physicochemical and biological characteris-
tics of Zarzio® [17], in four phase I studies in 146 healthy
volunteers and in a confirmatory phase III study for clinical
efficacy in 176 patients with breast cancer [18]. Moreover,
a retrospective study comparing the efficacy of Zarzio® to
a historical cohort treated with Neupogen® [19] and an
observational study [20] in patients with solid tumor or
hematological cancer demonstrated that Zarzio® prevented
chemotherapy-induced febrile neutropenia in ambulatory
care, without unexpected adverse events. Few data were
however available on the use of this biosimilar of
filgrastim outside the controlled experimental environment
of clinical trials. The objective of the present study was (1)
to improve knowledge on Zarzio® for efficacy and safety
in real-world conditions and (2) to understand how clini-
cians use Zarzio® in their clinical practice for the prophy-
laxis of chemotherapy-induced neutropenia.
Patients and methods
Study design
The Zarzio® Observational Study (ZOS) was an observa-
tional, prospective, longitudinal, and multicenter study,
performed in French cancer centers. The objective of the
study was to describe the prophylactic effect of Zarzio® on
the incidence of severe neutropenia (<500 neutrophils/
mm3) and to collect data on safety and conditions of use
in current clinical practice. The prescription of Zarzio® to a
patient was independent of the inclusion of this patient in
the study. The follow-up of each patient was a maximum of
6 cycles.
Inclusion criteria
Patients of both genders included in the study were aged of
18 years and older, received first-line chemotherapy for solid
tumor or non-Hodgkin lymphomawith a performance index ≤
3, and were treated with Zarzio® with either a risk of febrile
neutropenia>20 % or between 10 and 20 % with patient-
related risks of febrile neutropenia as described by EORTC.
Female patients must be postmenopausal for at least 1 year,
sterile, or used efficient contraception. The main exclusion
criteria were as follows: patient with grade 3 or 4 neutro-
penia (neutrophils <1×109/L or 1000/mm3), myeloid leu-
kemia, hypersensitivity to Zarzio® or to any other G-CSF,
hypersensitivity to Escherichia coli-derived proteins or
treatment by chemotherapy at high doses.
The patients were informed both orally and in writing
on the objectives of the study. This study was conducted
according to the current revision of the 1964 Helsinki dec-
laration and with the French laws and regulations.
Data collected
Data of each patient were collected in an electronic case report
form by the study physicians: sociodemographic data of in-
vestigator and patient, characteristics of cancer disease, num-
ber of chemotherapy treatments, type of chemotherapy, total
scheduled dose and total administered dose, scheduled inter-
val between chemotherapy cycles, risk factors of
chemotherapy-induced neutropenia, number of neutrophils
during follow-up, adverse events, clinical and biological data,
treatment with Zarzio® (date of onset, duration of treatment,
and dosage), episodes of febrile neutropenia, and use of anti-
biotics. Data were collected at each cycle of chemotherapy.
Statistical analysis
The primary endpoint of the study was the comparison of
the incidence of severe neutropenia at nadir between the
1st and the 4th cycle under treatment with Zarzio®. The
expected incidence of severe neutropenia (grade 4: < 500
neutrophils/mm3) at nadir was approximately 40 % for the
1st cycle of chemotherapy and 25 % for the 4th cycle [12].
In order to detect a decrease of 15 % of the incidence of
severe neutropenia with an alpha-risk at 5 % and a statis-
tical power at 80 %, 150 patients were needed. With a rate
of 20 % of non evaluable patients, 200 patients must be
included. This analysis could not be performed due to the
lack of data on neutrophil rates at nadir. This study allowed
nevertheless collecting data on efficacy, safety and condi-
tions of use of Zarzio®. Clinical and hematological param-
eters during the follow-up were analyzed in the population
of patients treated with Zarzio®.
The relative dose intensity (RDI) was calculated at
each cycle (total dose of chemotherapy administered dur-
ing a cycle divided by the total dose scheduled for the
same cycle).
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Results
Characteristics of study physicians
Among the 14 study physicians, 9 were male and they had
a median of 18 years of practice (from 3 to 36 years). Nine
practiced in general/university hospitals, 3 in specialized
cancer centers, and 2 in private clinics. About the use of G-
CSF in chemotherapy-induced neutropenia, 11 out 14 re-
ported to refer to the guidelines of EORTC, and the 3 other
physicians referred to ASCO recommendations.
Disposition of patients
Figure 1 summarizes the disposition of the 184 patients
included in the study during the chemotherapy cycles
and, among them, those who received Zarzio®. The medi-
an duration of follow-up of patients was 110 days (range
from 28 to 243 days). A total of 32 patients (17.4 %)
discontinued the study, most frequently due to disease
progression.
Characteristics of patients
The characteristics of the 184 patients at inclusion are de-
scribed in Table 1. The study population had a median age
of 64 years, and two-third were women. Chemotherapy was
administered for solid tumor for 89.7 % of patients, mainly
breast cancer (50.5 %); 10.3 % of patients (19/184) had
non-Hodgkin lymphoma. The median time interval be-
tween diagnosis and inclusion was 1.7 months, and mean
was 10.2 months.
Among patients with solid tumor, tumoral stage was T3 for
20.1 % and T4 for 11.0 %; there was stage N1 or more of
lymph node involvement for 52.1% (85/163), and 20.2% (33/
163) had metastases (stage M1). Nineteen patients among the
33 stage M1 patients had a metastatic relapse that was diag-
nosed with a median of 2.1 months before inclusion. Among
patients with non-Hodgkin lymphoma, 42.1 % (8/19)
achieved stage IV (classification of Ann Arbor).
Risk factors of neutropenia
The risk factors of febrile neutropenia were assessed before
the first cycle of chemotherapy: 32.1 % (59/184) of patients
had a risk of febrile neutropenia >20 %; 55.4 % (102/184) of
patients had a risk between 10 and 20 %, and for 12.5 % (23/
184), the risk was <10 % (Table 2). The patient-related risk
factors increasing the overall risk of febrile neutropenia were
as follows: age>65 years for 45 % (82/184) of patients, con-
comitant at-risk diseases for 20% (36/184), and hemoglobin<
12 g/dL for 25 % (46/184). Among the patients with a risk of
febrile neutropenia<10 %, 9/23 had an age above 65 years, 6/
23 had a concomitant at-risk disease, and 8/23 had
hemoglobin<12 g/dL (Table 2).
Cycles of chemotherapy
For most patients, the scheduled number of cycles was be-
tween 3 and 6 (96.2 %; 177/184) and, for the majority, 6
cycles were scheduled (70.1 %; 129/184) (Table 1). Most
frequently, the scheduled time interval between 2 cycles was





Patients included per cycle/ 
Patients treated with Zarzio®
● Cycle 1 : 184/184 
● Cycle 2 : 181/170 
● Cycle 3 : 172/165 
● Cycle 4 : 148/134 
● Cycle 5 : 121/107 
● Cycle 6 : 114/98 
Study discontinuations, n=32 (17.4%) 
● Serious adverse event, n=2 
● Death, n=3 
● Lost to follow-up, n=2 
● Other (disease progression), n=25 
Excluded patients, n=21 (10.2%) 
● Not in 1st line of chemotherapy, n=13 
● Neutropenia, n=3 
● Not meeting other inclusion criteria or 
administrative reasons, n=7 
Fig. 1 Disposition of patients
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The RDI administered for the included population varied
from 96 to 99 % between cycle 1 and cycle 6; the rate of
patients with RDI≥85 % varied from 89 to 99 % between
cycle 1 and cycle 6.
A modification of chemotherapy protocol occurred for
47.8 % of patients (88/184): decrease>15 % of scheduled
dose (29.5 %; 26/88), increase of the scheduled duration be-
tween 2 cycles (70.5 %; 62/88), or change of the number of
scheduled cycles (35.2 %; 31/88).
Overall, chemotherapy began according to the initial
schedule in 85.9 % of cases. When it was not the case,
neutropenia was responsible for this administration delay in
19.8 % of cases.
Surgery of tumor was scheduled during chemotherapy for
four patients (2.2 %) (during cycle 3 for the four patients).
Radiotherapy was scheduled during at least one cycle for three
patients (cycle 1; cycles 1 and 2; cycle 3).
Treatment with Zarzio®
Table 3 describes the conditions of administration and expo-
sition to Zarzio® during the 6 chemotherapy cycles. The mean
dose was stable during the 6 cycles (approximately 33 MIU
per day; median, 30 MIU per day) with a median number of 5
injections per cycle. The mean duration between the onset of
chemotherapy cycle and the onset of Zarzio® administration
varied from3.6 to 4.5 days according to cycles (median, 3 days
for each cycle); the mean duration of exposition to Zarzio®
varied from 4.6 to 4.8 days (median, 5 days for each cycle).
All injections were done by a nurse (and not by a physician or
by the patient him/herself).
Rates of neutrophils during the follow-up
and chemotherapy-induced neutropenia
The mean rates of neutrophils between cycle 1 and cycle 6
progressively decreased from 4584 to 3601/mm3 in patients
treated with Zarzio (Table 4). This decrease mainly occurred
after the first chemotherapy cycle and remained nearly stable
for the next cycles. Accordingly, the rate of grade 1–2 neutro-
penia (1000–2000 neutrophils/mm3) mostly increased after
the first cycle: 5.6, 20.5, 16.1, 24.4, 23.4, and 31.6 % for each
of the 6 successive cycles. Only one grade 4 neutropenia was
observed (after cycle 1).
No case of febrile neutropenia was reported during the
study. Neutropenia led to hospitalization and/or antibiotic
treatment in 10 patients (hospitalization with antibiotic treat-
ment, n=2; hospitalization without antibiotic treatment, n=4;
antibiotic treatment without hospitalization, n=4).
Other hematological and clinical parameters
The clinical parameters (body mass index, temperature, per-
formance status) remained stable during the study in the pop-
ulation of patients treated with Zarzio (Table 5).
As for neutrophils, the means of the other hematological
parameters decreased between cycle 1 and cycle 6 in the pop-
ulation of patients treated with Zarzio: leucocytes from 7479
to 6137/mm3; lymphocytes from 1733 to 1330/mm3; and Hb
from 12.8 to 11.2 g/dL (Table 5). The rates of platelets
remained relatively stable, from 279 to 266×109/L.
Table 1 Characteristics of patients at inclusion
Characteristics N=184
Female gender, n (%) 119 (64.7)
Age, years
Mean (SD) 61.7 (11.6)
Median (min–max) 64.0 (26–88)
Body mass index, kg/m2
Mean (SD) 26.7 (6.0)
Median (min–max) 25.8 (16.5–50.6)
Time interval since diagnosis, months
Mean (SD) 10.2 (30.0)
Median (min–max) 1.7 (0–228)
Type of primary tumor, n (%)
Non-Hodgkin lymphoma 19 (10.3)
Solid tumor 165 (89.7)
Breast cancer 93 (50.5)
Lung cancer 13 (7.1)
Other solid tumor 59 (32.1)
Patients with metastases (stage M1) 33 (20.2)*








Previous treatments, n (%)
Radiotherapy 27 (14.7)
Surgery 98 (53.3)
Hormone therapy 13 (7.1)




Other (1, 2, 5, 8) 10 (5.4)
*Two patients with missing data
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Safety
Overall, 15.8 % (29/184) of patients had at least one adverse
event related to Zarzio® according to the investigator’s judg-
ment. An analysis of each cycle showed that this rate progres-
sively decreased throughout the 6 cycles: from 7.7 % (14/181)
during cycle 2 to 2.6 % (3/114) during cycle 6. The most
frequent adverse event related to Zarzio® was pain, in partic-
ular bone pain (n=15 patients).
There were three deaths due to cancer disease. Serious
adverse events were reported for 2 patients (1.1 %); none of
them was considered to be related to Zarzio® (one adverse
event was related to chemotherapy and the other one was
due to the general condition requiring chemotherapy discon-
tinuation). The study was discontinued for these two patients.
One case of intolerance to Zarzio® (lingual edema) led to
study discontinuation. Most of the other study discontinua-
tions were related to disease progression (Fig. 1).
Discussion
The strength of this non-interventional study rests on the fol-
lowing points: a relatively large number of patients (n=184)
followed in the usual conditions of administration of Zarzio®;
a high percentage of patients with a risk of febrile neutrope-
nia>20 % (32.1 %) or between 10 and 20 % (55.4 %); a high
percentage of elderly patients (44.6 % of patients>65 years); a
low number of patients lost to follow-up (6.3 %); data on
hematological parameters between each cycle with very few













Time interval between onset of chemotherapy and onset of Zarzio®, days
Mean (SD) 3.8 (2.2) 3.9 (2.3) 4.5 (4.8) 3.7 (2.3) 3.9 (2.2) 3.6 (2.0)
Median 3.0 3.0 3.0 3.0 3.0 3.0
Range 1–9 1–9 1–33 1–9 1–10 0–8
Dosage of Zarzio®, MIU/day
Mean (SD) 33.1 (6.8) 32.9 (6.6) 32.6 (6.5) 32.7 (6.4) 33.1 (6.8) 33.5 (7.1)
Median 30.0 30.0 30.0 30.0 30.0 30.0
Range 30–48 30–48 30–60 30–48 30–48 30–48
Number of injections of Zarzio®
Mean (SD) 4.7 (1.2) 4.8 (1.2) 4.7 (1.2) 4.6 (1.4) 4.5 (1.3) 4.5 (1.3)
Median 5.0 5.0 5.0 5.0 5.0 5.0
Range 2–7 2–7 2–7 2–10 2–8 2–8
Exposition to Zarzio®, days
Mean (SD) 4.8 (1.3) 4.8 (1.3) 4.8 (1.2) 4.6 (1.4) 4.6 (1.4) 4.6 (1.3)
Median 5.0 5.0 5.0 5.0 5.0 5.0
Range 2–9 2–9 2–9 2–10 2–9 2–9
Table 2 Assessment of the risk of chemotherapy-induced febrile neutropenia and patient-related factors increasing this risk
Patient-related factors increasing the risk of febrile neutropenia Risk of febrile neutropenia, n (%) Total (n=184)
<10 % (n=23) 10–20 % (n=102) >20 % (n=59)
Age>65 years, n (%) 9 (39) 43 (42) 30 (51) 82 (45)
Concomitant disease, n (%) 6 (26) 17 (17) 13 (22) 36 (20)
Hepatic, n 0 5 3 8
Renal, n 0 1 0 1
Cardiovascular, n 1 9 1 11
Other, n 6 10 10 26
Hemoglobin<12 g/dL, n (%) 8 (35) 22 (22) 16 (27) 46 (25)
No patient-related factors, n (%) 0 20 (20) 0 20 (11)
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Table 5 Clinical and
hematological parameters during
the follow-up (population of pa-













Body mass index, kg/m2
Mean (SD) 26.7 (6.0) 26.8 (6.2) 26.7 (6.1) 27.3 (5.9) 27.1 (5.5) 26.8 (5.0)
Median 25.8 25.8 25.7 26.3 26.3 26.7
MD 1 0 2 0 0 3
Performance status (OMS), n (%)
0 108 (63.9) 87 (61.7) 82 (60.7) 71 (65.7) 59 (69.4) 49 (66.2)
1 55 (32.5) 50 (35.5) 48 (35.6) 34 (31.5) 23 (27.1) 25 (33.8)
2 6 (3.6) 4 (2.8) 4 (3.0) 3 (2.8) 3 (3.5) 0
3 0 0 1 (0.7) 0 0 0
MD 15 29 30 26 22 24
Temperature, °C
Mean (SD) 37.0 (0.2) 37.0 (0.1) 37.0 (0.2) 37.0 (0.1) 37.0 (0.2) 37.0 (0.1)
Median 37.0 37.0 37.0 37.0 37.0 37.0
MD 37 37 36 31 23 25
Leucocytes/mm3
Mean (SD) 7479 (5151) 6705 (4835) 6755 (4514) 5960 (6128) 6186 (4158) 6137 (5087)
Median 6520 5700 5800 4810 5300 5100
MD 1 3 4 4 0 0
Lymphocytes/mm3
Mean (SD) 1733 (760) 1665 (788) 1493 (691) 1322 (549) 1402 (709) 1330 (871)
Median 1586 1539 1354 1271 1280 1109
MD 2 5 7 6 1 0
Platelets×109/L
Mean (SD) 279 (84) 312 (128) 280 (110) 279 (105) 276 (113) 266 (80)
Median 273 284 270 267 259 260
MD 3 3 5 3 0 1
Hemoglobin, g/dL
Mean (SD) 12.8 (1.6) 12.0 (1.3) 11.7 (1.2) 11.6 (1.2) 11.4 (1.2) 11.2 (1.2)
Median 12.9 12.1 11.8 11.7 11.3 11.1
MD 2 4 5 4 1 3
MD missing data














Mean (SD) 4584 (3492) 3665 (1897) 3980 (2868) 3239 (1777) 3389 (1918) 3601 (3494)
Median 3969 3354 3360 2890 3028 3169
Range 1000–38,219 460–9996 530–27,770 951–12,270 611–11,377 1037–33,830
Neutropeniaa, n (%)
Grade 1 5 (2.8) 18 (10.8) 14 (8.7) 20 (15.3) 14 (13.1) 17 (17.3)
Grade 2 5 (2.8) 16 (9.6) 12 (7.5) 12 (9.2) 11 (10.3) 14 (14.3)
Grade 3 0 1 (0.6) 1 (0.6) 2 (1.5) 4 (3.7) 0
Grade 4 0 1 (0.6) 0 0 0 0
MD 3 4 4 3 0 1
MD missing data
a Grades of neutropenia: Grade 1, [1500–2000[; Grade 2, [1000–1500[; Grade 3, [500–1000[; Grade 4, < 500/mm3
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missing data and high RDI (>95 % for 83.2 % of patients, all
cycles). There are nevertheless some limitations due precisely
to the observational and non-stringent conditions of the study.
Thus, the primary endpoint (comparison of the incidence
of severe neutropenia between cycle 1 and cycle 4) could
not be assessed.
Most of the study physicians referred to the EORTC recom-
mendations for primary prophylaxis of febrile neutropenia [13].
According to these recommendations, G-CSF administration is
based on an expected risk of febrile neutropenia≥20 % related
to the type of chemotherapy. Patient-related risk factors such as
age>65 years, history of febrile neutropenia, female gender,
Hb<12 g/dL or concomitant hepatic, renal or cardiovascular
disease are taken into account for the decision to treat patients
with a risk of febrile neutropenia between 10 and 20 %.
Half of the study patients were women with breast cancer.
Almost half of patients had an age >65 years and about one
third had a risk of febrile neutropenia>20 %. In this high-risk
population, no case of febrile neutropenia was reported. Neu-
tropenia led to hospitalization and/or antibiotic treatment in 10
patients. Even in the absence of control group, these results
confirm the efficacy of the prophylactic treatment in patients
consecutively included without selection criteria, apart for the
indication of prophylaxis with G-CSF.
Analysis of hematological parameters evidences that the
rates of neutrophils decreased between cycle 1 and cycle 2
and remained then relatively stable in normal ranges (>2000
neutrophils/mm3). These data validate in usual clinical condi-
tions the results of a phase III study that assessed Zarzio® in
170 womenwith breast cancer; the most important decrease of
the rates of neutrophils was also observed after the first cycle
of chemotherapy. In the retrospective study of Verpoort and
Möhler in 77 patients treated with Zarzio®, the efficacy of
Zarzio® was comparable to Neupogen®; one patient in each
treatment group had an episode of febrile neutropenia [19].
The most frequent adverse event related to Zarzio® in our
study was pain, more particularly bone pain. These adverse
events were expected, and they are considered as very frequent
(≥10 %) in the Summary of Product Characteristics of Zarzio®
in cancer patients treated withG-CSF [21]. No serious adverse
event related to Zarzio® was reported in the 184 study
patients. The study discontinuations were most often relat-
ed to disease progression.
Compared to original filgrastim, Zarzio® has a greater
affordability that should encourage the use of G-CSF as
recommended by guidelines. Indeed, with the financial
constraints on healthcare cost systems, biosimilars offer
clinically effective alternative, and Zarzio® should improve
access to expensive biological treatments for patients [22].
Moreover, the use and handling of the pre-filled syringes of
Zarzio® is easy [23].
In conclusion, this non-interventional study allowed im-
proving knowledge on Zarzio®, biosimilar of Neupogen®,
in current clinical practice. The results obtained in real-life
conditions confirm that Zarzio® is efficient and well tolerated
in cancer patients.
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